37 results on '"Noel, Alan R."'
Search Results
2. Antibacterial effect of seven days exposure to ceftolozane-tazobactam as monotherapy and in combination with fosfomycin or tobramycin against Pseudomonas aeruginosa with ceftolozane-tazobactam MICs at or above 4 mg/l in an in vitro pharmacokinetic model
3. A pilot observational study of CSF vancomycin therapeutic drug monitoring during the treatment of nosocomial ventriculitis
4. Comparative bactericidal activity of representative β-lactams against Enterobacterales, Acinetobacter baumannii and Pseudomonas aeruginosa
5. Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection
6. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model
7. Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom Reference Center
8. Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection
9. Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection
10. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system
11. Antibacterial effect of imipenem/relebactam on aerobic Gram-negative bacilli: in vitro simulations of 7 or 14 day human exposures
12. Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection
13. Pharmacodynamics of inhaled amikacin (BAY 41-6551) studied in an in vitro pharmacokinetic model of infection
14. Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in anin vitropharmacokinetic model of infection
15. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection
16. Pharmacodynamics of Ceftaroline against Staphylococcus aureus Studied in anIn VitroPharmacokinetic Model of Infection
17. Pharmacodynamics of the Antibacterial Effect of and Emergence of Resistance to Doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an In Vitro Pharmacokinetic Model
18. Pharmacodynamics of Telavancin Studied in an In Vitro Pharmacokinetic Model of Infection
19. Bacterial Strain-to-Strain Variation in Pharmacodynamic Index Magnitude, a Hitherto Unconsidered Factor in Establishing Antibiotic Clinical Breakpoints
20. Pharmacodynamics of Minocycline against Staphylococcus aureus in an In Vitro Pharmacokinetic Model
21. Pharmacodynamics of the Antibacterial Effect and Emergence of Resistance to Tomopenem, Formerly RO4908463/CS-023, in an In Vitro Pharmacokinetic Model of Staphylococcus aureus Infection
22. Pharmacodynamics of Moxifloxacin against Anaerobes Studied in an In Vitro Pharmacokinetic Model
23. Pharmacodynamics of Ceftazidime plus the Serine β-Lactamase Inhibitor AM-112 against Escherichia coli Containing TEM-1 and CTX-M-1 β-Lactamases
24. Antibacterial Effects of Amoxicillin-Clavulanate against Streptococcus pneumoniae and Haemophilus influenzae Strains for Which MICs Are High, in an In Vitro Pharmacokinetic Model
25. Activity of AZD2563, a Novel Oxazolidinone, against Staphylococcus aureus Strains with Reduced Susceptibility to Vancomycin or Linezolid
26. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In VitroPharmacokinetic Model of Infection
27. Pharmacodynamics of Ceftaroline against Staphylococcus aureusStudied in an In VitroPharmacokinetic Model of Infection
28. Pharmacodynamics of the Antibacterial Effect of and Emergence of Resistance to Doripenem in Pseudomonas aeruginosaand Acinetobacter baumanniiin an In VitroPharmacokinetic Model
29. Pharmacodynamics of Telavancin Studied in an In VitroPharmacokinetic Model of Infection
30. Pharmacodynamics of Minocycline against Staphylococcus aureusin an In Vitro Pharmacokinetic Model
31. Antibacterial Effects of Amoxicillin-Clavulanate against Streptococcus pneumoniaeand Haemophilus influenzaeStrains for Which MICs Are High, in an In Vitro Pharmacokinetic Model
32. Pharmacodynamics of Ceftazidime plus the Serine β-Lactamase Inhibitor AM-112 against Escherichia coliContaining TEM-1 and CTX-M-1 β-Lactamases
33. Activity of AZD2563, a Novel Oxazolidinone, against Staphylococcus aureusStrains with Reduced Susceptibility to Vancomycin or Linezolid
34. Pharmacodynamics of piperacillin/tazobactam against Pseudomonas aeruginosa : antibacterial effect and risk of emergence of resistance.
35. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
36. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.
37. Pharmacodynamics of ceftazidime plus the serine beta-lactamase inhibitor AM-112 against Escherichia coli containing TEM-1 and CTX-M-1 beta-lactamases.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.